|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,152,997: Azithromycin Composition
U.S. Patent 5,152,997, titled "Azithromycin Composition," was granted on October 6, 1992, to Pfizer Inc. The patent claims a novel crystalline form of azithromycin, specifically a monohydrate crystalline form, which exhibits improved stability and handling characteristics compared to existing forms. This monohydrate form offers advantages in pharmaceutical manufacturing and formulation, potentially leading to more consistent and shelf-stable drug products. The patent's claims are directed towards this specific crystalline structure and its use in pharmaceutical compositions.
What is the Core Invention Claimed in U.S. Patent 5,152,997?
The central claim of U.S. Patent 5,152,997 is directed towards "A crystalline monohydrate of azithromycin." The patent details the methods for obtaining this specific crystalline form and its pharmaceutical utility. The invention differentiates itself by providing a stable, crystalline monohydrate of azithromycin, which addresses challenges associated with previously known forms of the antibiotic.
The claims specifically define the crystalline monohydrate of azithromycin based on its X-ray powder diffraction pattern. Key peaks are listed, providing a definitive fingerprint for the claimed crystalline form. This precise definition is critical for establishing novelty and non-obviousness over prior art.
What are the Key Characteristics of the Patented Azithromycin Monohydrate Form?
The patented azithromycin monohydrate form is characterized by its unique crystalline structure, as evidenced by its X-ray powder diffraction (XRPD) pattern. This specific crystalline morphology offers several advantages for pharmaceutical development and manufacturing:
- Improved Stability: The monohydrate form exhibits enhanced stability, particularly concerning the amorphous forms or other less defined crystalline structures of azithromycin that may be prone to degradation or changes in physical form over time. This stability is crucial for ensuring the shelf-life and efficacy of the drug product.
- Handling Properties: The crystalline nature of the monohydrate form generally leads to better flowability and compressibility compared to amorphous or less crystalline materials. These properties are vital for efficient tablet manufacturing, capsule filling, and other pharmaceutical processing steps.
- Purity: A well-defined crystalline form often facilitates purification processes, potentially leading to higher purity azithromycin active pharmaceutical ingredient (API).
The patent details the process for preparing this crystalline monohydrate, often involving controlled crystallization techniques from specific solvent systems. The ability to reliably produce this specific form is a cornerstone of the patent's enablement.
What are the Specific Claims Made in U.S. Patent 5,152,997?
U.S. Patent 5,152,997 contains multiple claims that define the scope of the invention. The primary claims are directed towards the crystalline monohydrate itself and pharmaceutical compositions containing it.
Independent Claims typically include:
- Claim 1: This is often the broadest claim, directed to "A crystalline monohydrate of azithromycin." The claim would further define this crystalline monohydrate by its characteristic X-ray powder diffraction pattern, listing specific peak positions (2θ values). For example, it might list peaks at approximately 6.7°, 7.6°, 8.7°, 10.1°, 12.4°, 12.9°, 14.7°, 16.2°, 17.6°, 18.2°, 19.5°, 20.1°, 20.8°, 21.6°, 22.7°, 23.2°, 23.8°, 24.4°, 25.0°, 26.4°, 27.1°, 27.5°, 28.5°, 29.1°, 30.0°, 30.7°, 31.5°, 32.8°, 33.9°, 35.0°, 35.7°, 36.5°, and 37.2° ± 0.2° 2θ. (Note: Specific peaks and their intensity relative to the strongest peak are crucial details typically included in the patent claims for definitive identification).
- Dependent Claims: These claims would further refine or limit the scope of the independent claims. Examples include claims directed to:
- The crystalline monohydrate as defined in Claim 1, wherein the crystalline monohydrate has a differential scanning calorimetry (DSC) endotherm of about 178°C.
- The crystalline monohydrate as defined in Claim 1, wherein the crystalline monohydrate has a thermogravimetric analysis (TGA) weight loss of about 3.0-3.5% between 70°C and 150°C, corresponding to the loss of one molecule of water.
- A pharmaceutical composition comprising the crystalline monohydrate of azithromycin as defined in Claim 1 and a pharmaceutically acceptable carrier.
- A method of treating a bacterial infection, comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline monohydrate of azithromycin.
The precise wording and numerical values for XRPD peaks, DSC temperatures, and TGA ranges are critical and found within the full patent document. These specific parameters are used to distinguish the patented form from other known or potential crystalline polymorphs of azithromycin.
How Does the Patented Azithromycin Form Compare to Other Known Forms?
Azithromycin, as an active pharmaceutical ingredient, can exist in various physical forms, including amorphous solids and different crystalline polymorphs. Polymorphs are crystalline solids that have the same chemical composition but differ in their crystal lattice structure. These structural differences can significantly impact a drug's physical and chemical properties, such as:
- Solubility: Different polymorphs can exhibit varying dissolution rates, affecting bioavailability.
- Stability: Some polymorphs are more stable than others under specific environmental conditions (temperature, humidity), influencing shelf life.
- Manufacturability: Properties like flowability, compressibility, and hygroscopicity can differ, impacting the ease and efficiency of pharmaceutical processing.
Prior to the development and patenting of the monohydrate form described in U.S. Patent 5,152,997, other forms of azithromycin were known. These might have included amorphous azithromycin or other crystalline forms with less desirable properties. The monohydrate form, as claimed, was specifically engineered or discovered to overcome these limitations.
Comparison Points:
| Property |
Amorphous Azithromycin |
Other Crystalline Forms (Hypothetical) |
U.S. Patent 5,152,997 Monohydrate |
| Crystalline State |
Non-crystalline, disordered atomic arrangement. |
Ordered atomic arrangement in a specific lattice. |
Ordered atomic arrangement with a defined water molecule in the lattice. |
| Stability |
Generally less stable, prone to conversion to crystalline forms or degradation. |
Varies; can be more stable than amorphous but potentially less so than the patented monohydrate. |
Enhanced stability, particularly against degradation and polymorphic conversion. |
| Solubility/Dissolution |
Often exhibits higher initial solubility but can be less predictable. |
Varies based on polymorph; can be slower or faster than amorphous. |
Predictable dissolution profile, contributing to consistent bioavailability. |
| Manufacturability |
Can have poor flow and compressibility. |
Varies; can be improved over amorphous forms. |
Improved flowability and compressibility for efficient processing. |
| Water Content |
Typically anhydrous. |
Varies; can be anhydrous or hydrated (different hydrates). |
Specifically contains one molecule of water per molecule of azithromycin. |
The patent's strength lies in demonstrating that this specific crystalline monohydrate form possesses a unique and advantageous combination of properties that were not readily apparent or achievable with prior art forms of azithromycin.
What is the Patent Landscape for Azithromycin?
The patent landscape for azithromycin is complex, reflecting its long history as a widely used antibiotic and the ongoing efforts to develop improved formulations, delivery methods, and new therapeutic uses. U.S. Patent 5,152,997 represents a foundational patent related to the physical form of the active ingredient itself.
Key aspects of the azithromycin patent landscape include:
- Composition of Matter Patents: The original patents covering the azithromycin molecule itself have long expired. These are the strongest form of patent protection, covering the compound regardless of how it is made or used.
- Process Patents: Patents covering specific methods of synthesizing azithromycin. These can be critical for generic manufacturers to design around existing patented processes.
- Formulation Patents: Patents claiming specific pharmaceutical compositions designed to improve drug delivery, stability, patient compliance, or therapeutic efficacy. This includes patents on controlled-release formulations, specific excipient combinations, or novel dosage forms.
- Polymorph Patents: Like U.S. Patent 5,152,997, patents claiming specific crystalline forms (polymorphs) or amorphous forms of the active pharmaceutical ingredient. These can extend market exclusivity by protecting a superior or novel physical form of the drug.
- Method of Use Patents: Patents claiming new therapeutic uses for azithromycin, such as treating different diseases or conditions, or using it in specific treatment regimens.
- Pediatric Exclusivity: The U.S. Food and Drug Administration (FDA) can grant an additional six months of marketing exclusivity for drug products if the sponsor submits acceptable data to meet written requests for pediatric studies.
U.S. Patent 5,152,997 falls into the category of polymorph patents. Its expiration (and that of related patents covering other advantageous forms) would have allowed for the development and marketing of generic azithromycin products that could utilize these specific crystalline forms. However, the existence of other formulation or method of use patents could still pose market entry barriers for generic competitors even after the expiration of the original composition of matter and key polymorph patents.
What is the Expiration Date of U.S. Patent 5,152,997?
U.S. Patent 5,152,997 was granted on October 6, 1992. Under U.S. patent law at the time of its application (which preceded the Hatch-Waxman Act's patent term extension provisions fully coming into effect for all applications), the standard patent term was 17 years from the date of grant for patents filed before June 8, 1995.
Therefore, the original expiration date of U.S. Patent 5,152,997 was October 6, 2009.
It is important to note that patent term extensions (PTE) or adjustments can apply to U.S. patents for pharmaceutical products to compensate for delays in FDA regulatory review. However, for a patent granted in 1992, the primary term is the dominant factor unless specific extensions were sought and granted. A thorough check of the patent's official USPTO file history would confirm if any PTE or adjustment was applied, but the original term is calculated as described.
What is the Commercial Significance of a Patented Crystalline Form?
The commercial significance of patenting a specific crystalline form of an active pharmaceutical ingredient (API) like azithromycin is substantial, particularly in the context of extending market exclusivity and safeguarding product quality.
-
Extended Market Exclusivity: The most direct commercial benefit is the ability to extend market exclusivity beyond the expiration of the original composition of matter patent. If the patented crystalline form offers superior properties (e.g., stability, manufacturability, bioavailability) and is essential for producing a viable drug product, it can prevent generic competitors from launching their products until the polymorph patent expires. This allows the innovator company to recoup R&D investments and maximize profits.
-
Barrier to Generic Entry: Even if the basic azithromycin molecule is off-patent, generic manufacturers must be able to produce the drug economically and to regulatory standards. If the innovator's patented crystalline form is the most stable, easiest to process, or most bioavailable, generic companies may face significant challenges in developing their own non-infringing crystalline forms or may need to invest heavily in developing alternative processes and forms that meet therapeutic standards.
-
Quality Control and Assurance: Patented crystalline forms provide a clear standard for the API's physical characteristics. This is crucial for ensuring consistent drug quality, efficacy, and safety. A well-defined crystalline form is less prone to batch-to-batch variability, which can occur with amorphous materials or mixtures of polymorphs. This control is invaluable for pharmaceutical manufacturing.
-
Improved Drug Product Performance: As highlighted with azithromycin monohydrate, improved stability can lead to longer shelf-lives, reducing product wastage. Better handling properties can lower manufacturing costs. Consistent dissolution profiles can ensure reliable therapeutic outcomes for patients. These improvements translate into a superior commercial product.
-
Litigation and Defense: Polymorph patents are frequently litigated. Innovator companies use them to challenge generic drug applications. The ability to demonstrate infringement of a polymorph patent can halt or delay generic market entry, providing significant commercial leverage.
In essence, patenting a specific crystalline form transforms a commodity API into a proprietary product by protecting its physical manifestation, which is critical for its pharmaceutical performance and commercial viability.
Key Takeaways
- U.S. Patent 5,152,997 claims a specific crystalline monohydrate form of azithromycin, characterized by its X-ray powder diffraction pattern.
- This monohydrate form offers advantages in pharmaceutical stability and handling properties compared to other potential forms of azithromycin.
- The patent's claims are directed towards the specific crystalline structure and its inclusion in pharmaceutical compositions.
- The original expiration date of U.S. Patent 5,152,997 was October 6, 2009.
- Patenting specific crystalline forms is a key strategy for extending market exclusivity and creating barriers to generic competition in the pharmaceutical industry.
Frequently Asked Questions
-
What specific advantages does the monohydrate crystalline form of azithromycin offer over amorphous azithromycin?
The monohydrate form generally exhibits enhanced physical stability, reducing the risk of polymorphic conversion or degradation over time, and better handling characteristics such as flowability and compressibility, which are critical for efficient pharmaceutical manufacturing.
-
Can generic manufacturers use the crystalline monohydrate form of azithromycin after the expiration of U.S. Patent 5,152,997?
Assuming no other overlapping patents (e.g., formulation or method of use patents) block its use, generic manufacturers could potentially utilize the crystalline monohydrate form after the expiration of U.S. Patent 5,152,997. However, they must ensure their product is non-infringing of any still-active patents.
-
How is a specific crystalline form of a drug identified and protected by a patent?
A specific crystalline form is identified by its unique physical properties, primarily its X-ray powder diffraction (XRPD) pattern, but also including characteristics like differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Patents protect these forms by defining them through these characteristic analytical data.
-
Does the expiration of a polymorph patent mean all patents related to azithromycin have expired?
No. U.S. Patent 5,152,997 covers a specific crystalline form. Other patents related to azithromycin may exist, covering different crystalline forms, amorphous forms, novel formulations (e.g., extended-release), manufacturing processes, or new therapeutic uses. These may still be in force.
-
What role does the water content play in defining the patented azithromycin monohydrate?
The "monohydrate" designation specifically indicates that the crystalline lattice incorporates one molecule of water for each molecule of azithromycin. This precise hydration state is crucial to the crystal's structure and properties and is a defining characteristic claimed in the patent.
Citations
[1] Pfizer Inc. (1992). Azithromycin Composition. U.S. Patent 5,152,997. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
